Importance Chronic lymphocytic leukemia (CLL), defined by a minimum of 5× 10 9/L
monoclonal B cells in the blood, affects more than 200 000 people and is associated with …

Background The treatment landscape for chronic lymphocytic leukemia (CLL) continues to
undergo considerable evolution. Optimal selection of initial therapy from multiple effective …

Background Randomized trials of venetoclax plus anti-CD20 antibodies as first-line
treatment in fit patients (ie, those with a low burden of coexisting conditions) with advanced …

Bruton tyrosine kinase inhibitors (BTKi) have transformed the therapeutic landscape of
chronic lymphocytic leukaemia (CLL) and non‐Hodgkin lymphoma. However, primary and …

The treatment landscape for patients with chronic lymphocytic leukemia (CLL) has changed
considerably with the introduction of very effective oral targeted therapies (such as Bruton …

The oral, highly selective Bcl2 inhibitor venetoclax has substantially improved the
therapeutic landscape of chronic lymphocytic leukemia (CLL). Despite the remarkable …

Before targeted therapies, patients with higher-risk chronic lymphocytic leukemia (CLL),
defined as del (17p) and/or TP53 mutation (TP53 m), unmutated immunoglobulin heavy …

Undetectable measurable residual disease (uMRD) is achievable in patients with chronic
lymphocytic leukemia (CLL) with the BCL2-inhibitor venetoclax alone or combined with the …

While the past decade has witnessed unprecedented progress for patients with chronic
lymphocytic leukemia (CLL), outcomes for patients with Richter transformation (RT) remain …

Background: Small molecules targeting Bruton's tyrosine kinase (BTK) and B-cell lymphoma-
2 have become the standard of care for the treatment of chronic lymphocytic leukemia (CLL) …